Syphilis cases are rising, but many people don't know symptoms
Syphilis cases are on the rise around the globe, but many Americans don't know the symptoms.
Jun 12, 2024
0
0
Syphilis cases are on the rise around the globe, but many Americans don't know the symptoms.
Jun 12, 2024
0
0
Using a combination of cutting-edge immunologic technologies, researchers have successfully stimulated animals' immune systems to induce rare precursor B cells of a class of HIV broadly neutralizing antibodies (bNAbs). The ...
May 30, 2024
0
93
HIV has proven a hard target for vaccine design. The most promising approach, germline-targeting (GT), proposes a series of immunizations: a first shot to activate inexperienced B cells—antibody-producing white blood cells—followed ...
May 21, 2024
0
17
An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial.
May 17, 2024
0
63
A team led by the Duke Human Vaccine Institute (DHVI) has developed a vaccine approach that works like a GPS, guiding the immune system through the specific steps to make broadly neutralizing antibodies against HIV.
May 9, 2024
0
12
U.S. health officials are warning of an increase in rare bacterial illnesses than can lead to meningitis and possible death.
Mar 28, 2024
0
1
As the HIV virus glides up outside a human cell to dock and possibly inject its deadly cargo of genetic code, there's a spectacularly brief moment in which a tiny piece of its surface snaps open to begin the process of infection.
Feb 2, 2024
0
111
In December, the journal Vaccines published an analysis of COVID-19 vaccination coverage among people with HIV in Catalonia between December 2020 and July 2022. The study led by the Center for Epidemiological Studies on HIV/AIDS ...
Feb 2, 2024
0
0
Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV vaccine for people. The ...
Jan 17, 2024
0
68
The path to a successful HIV vaccine depends on a critical first step—activating specific immune cells that induce broadly neutralizing antibodies.
Jan 5, 2024
0
51
An HIV vaccine is a hypothetical vaccine against HIV, the etiological agent of AIDS. As there is no known cure for AIDS, the search for a vaccine has become part of the struggle against the disease.
The urgency of the search for a vaccine against HIV stems from the AIDS-related death toll of over 25 million people since 1981. Indeed, in 2002, AIDS became the primary cause of mortality due to an infectious agent in Africa.
Alternative medical treatments to a vaccine do exist. Highly active antiretroviral therapy (HAART) has been highly beneficial to many HIV-infected individuals since its introduction in 1996 when the protease inhibitor-based HAART initially became available. HAART allows the stabilization of the patient’s symptoms and viremia, but they do not cure the patient of HIV, nor of the symptoms of AIDS. And, importantly, HAART does nothing to prevent the spread of HIV through people with undiagnosed HIV infections. Safer sex measures have also proven insufficient to halt the spread of AIDS in the worst affected countries, despite some success in reducing infection rates.
Therefore, an HIV vaccine is generally considered as the most likely, and perhaps the only way by which the AIDS pandemic can be halted. However, after over 20 years of research, HIV-1 remains a difficult target for a vaccine.
The human body can defend itself against HIV, as work with monoclonal antibodies (MAb) has proven. That certain individuals can be asymptomatic for decades after infection is encouraging.
This text uses material from Wikipedia, licensed under CC BY-SA